An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday. The results presented at the American College of Cardiology scientific meeting in Washington provided a glimmer of hope that the medicine may have value. "I'm convinced there is a signal here of efficacy," said Dr. Harvey White, co-chair of the Glaxo-sponsored international study. The real test of the drug, darapladib, is likely to come from a second, late stage study in far less stable patients who received the medicine within 30 days of a heart attack.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment